FDA IRB inspections: What, why and how

By CenterWatch
Published: March 2017

Professionals enter the clinical trial enterprise every day who may be unfamiliar with the FDA regulations and inspections of clinical trial-related activities. This white paper serves as an introduction to colleagues who are new to the industry and as a refresher for the more experienced professional, but may have never undergone an FDA inspection. This paper is a good resource and an informative guide for what to expect during an FDA IRB inspection.

To learn more register for our free white paper FDA IRB Inspections: What, Why and How?.

Please enter in your information below. Fields with an * are required.

Please enter a valid email address to receive an email with a link to download the white paper.   

Please check the types of email communications you would like to receive:

CenterWatch offers a range of white papers for download that investigate and analyze current trends in the clinical trials industry and the impact they have on the research community.

Recent titles from CenterWatch:

Mobile health picks up momentum

Lack of clinical data overshadows opioid prescribing guidelines

CROs begin consolidating site landscape